X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA LUPIN LTD NATCO PHARMA/
LUPIN LTD
 
P/E (TTM) x 33.8 16.6 204.1% View Chart
P/BV x 17.2 3.9 446.0% View Chart
Dividend Yield % 0.7 0.8 83.3%  

Financials

 NATCO PHARMA   LUPIN LTD
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
LUPIN LTD
Mar-16
NATCO PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs8772,127 41.2%   
Low Rs4241,294 32.7%   
Sales per share (Unadj.) Rs223.4304.1 73.5%  
Earnings per share (Unadj.) Rs31.150.4 61.6%  
Cash flow per share (Unadj.) Rs40.360.7 66.4%  
Dividends per share (Unadj.) Rs5.007.50 66.7%  
Dividend yield (eoy) %0.80.4 175.4%  
Book value per share (Unadj.) Rs219.5243.8 90.0%  
Shares outstanding (eoy) m33.07450.58 7.3%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.95.6 51.7%   
Avg P/E ratio x20.933.9 61.7%  
P/CF ratio (eoy) x16.128.2 57.3%  
Price / Book Value ratio x3.07.0 42.2%  
Dividend payout %16.114.9 108.1%   
Avg Mkt Cap Rs m21,504770,740 2.8%   
No. of employees `000NA16.4 0.0%   
Total wages/salary Rs m1,12821,077 5.4%   
Avg. sales/employee Rs ThNM8,379.6-  
Avg. wages/employee Rs ThNM1,289.0-  
Avg. net profit/employee Rs ThNM1,388.7-  
INCOME DATA
Net Sales Rs m7,389137,016 5.4%  
Other income Rs m1671,877 8.9%   
Total revenues Rs m7,556138,893 5.4%   
Gross profit Rs m1,79337,535 4.8%  
Depreciation Rs m3044,635 6.6%   
Interest Rs m366446 82.1%   
Profit before tax Rs m1,29034,330 3.8%   
Minority Interest Rs m46-88 -52.9%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m30911,536 2.7%   
Profit after tax Rs m1,02722,707 4.5%  
Gross profit margin %24.327.4 88.6%  
Effective tax rate %23.933.6 71.2%   
Net profit margin %13.916.6 83.9%  
BALANCE SHEET DATA
Current assets Rs m3,68197,790 3.8%   
Current liabilities Rs m3,12353,872 5.8%   
Net working cap to sales %7.632.1 23.6%  
Current ratio x1.21.8 64.9%  
Inventory Days Days8985 105.7%  
Debtors Days Days59121 48.4%  
Net fixed assets Rs m7,68586,379 8.9%   
Share capital Rs m331901 36.7%   
"Free" reserves Rs m6,670105,735 6.3%   
Net worth Rs m7,259109,844 6.6%   
Long term debt Rs m95553,739 1.8%   
Total assets Rs m11,957224,378 5.3%  
Interest coverage x4.577.9 5.8%   
Debt to equity ratio x0.10.5 26.9%  
Sales to assets ratio x0.60.6 101.2%   
Return on assets %11.710.3 112.9%  
Return on equity %14.220.7 68.5%  
Return on capital %20.721.2 97.7%  
Exports to sales %39.449.1 80.2%   
Imports to sales %5.77.4 76.6%   
Exports (fob) Rs m2,90867,244 4.3%   
Imports (cif) Rs m42110,199 4.1%   
Fx inflow Rs m3,44571,405 4.8%   
Fx outflow Rs m70317,807 3.9%   
Net fx Rs m2,74353,598 5.1%   
CASH FLOW
From Operations Rs m1,440-3,690 -39.0%  
From Investments Rs m-1,089-69,434 1.6%  
From Financial Activity Rs m-35358,126 -0.6%  
Net Cashflow Rs m-1-14,998 0.0%  

Share Holding

Indian Promoters % 52.0 46.6 111.7%  
Foreign collaborators % 1.5 0.2 735.0%  
Indian inst/Mut Fund % 7.8 11.3 69.4%  
FIIs % 16.6 31.9 52.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 10.1 257.4%  
Shareholders   25,395 98,259 25.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SUVEN LIFE  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SHASUN PHARMA  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS